BR112014003997A2 - composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição - Google Patents
composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composiçãoInfo
- Publication number
- BR112014003997A2 BR112014003997A2 BR112014003997A BR112014003997A BR112014003997A2 BR 112014003997 A2 BR112014003997 A2 BR 112014003997A2 BR 112014003997 A BR112014003997 A BR 112014003997A BR 112014003997 A BR112014003997 A BR 112014003997A BR 112014003997 A2 BR112014003997 A2 BR 112014003997A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- compound
- severity
- cancer
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161527453P | 2011-08-25 | 2011-08-25 | |
PCT/EP2012/066468 WO2013026914A1 (en) | 2011-08-25 | 2012-08-24 | Serine/threonine pak1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014003997A2 true BR112014003997A2 (pt) | 2017-03-21 |
Family
ID=46799208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014003997A BR112014003997A2 (pt) | 2011-08-25 | 2012-08-24 | composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição |
Country Status (11)
Country | Link |
---|---|
US (1) | US8637537B2 (pt) |
EP (1) | EP2748159A1 (pt) |
JP (1) | JP2014524456A (pt) |
KR (1) | KR20140062079A (pt) |
CN (1) | CN104024248A (pt) |
BR (1) | BR112014003997A2 (pt) |
CA (1) | CA2844729A1 (pt) |
HK (1) | HK1197232A1 (pt) |
MX (1) | MX2014002208A (pt) |
RU (1) | RU2014109897A (pt) |
WO (1) | WO2013026914A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104940200B (zh) | 2010-03-30 | 2019-06-28 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
MX363118B (es) * | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
CN103724276A (zh) * | 2013-12-13 | 2014-04-16 | 成都丽璟科技有限公司 | 一种由硝基苯胺制备苯并咪唑类化合物的新方法 |
WO2016025641A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and an egfr inhibitor and related methods |
CN107405333A (zh) * | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
WO2017144546A1 (en) | 2016-02-23 | 2017-08-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma |
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
WO2017205425A1 (en) * | 2016-05-24 | 2017-11-30 | President And Fellows Of Harvard College | Compounds for organic light emitting diode materials |
WO2018108627A1 (de) | 2016-12-12 | 2018-06-21 | Bayer Cropscience Aktiengesellschaft | Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen |
CA3056970A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
WO2019201848A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
CN108689901B (zh) * | 2018-05-05 | 2020-04-28 | 西北大学 | 一种氮杂环丙烯类化合物的合成方法 |
JPWO2020017569A1 (ja) | 2018-07-17 | 2021-12-02 | 日本ケミファ株式会社 | T型カルシウムチャネル阻害剤 |
CA3135344A1 (en) | 2019-03-29 | 2020-10-08 | Nippon Chemiphar Co., Ltd. | Use of t-type calcium channel blocker for treating pruritus |
EP3956446A1 (en) | 2019-04-17 | 2022-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders |
WO2021198511A1 (en) | 2020-04-03 | 2021-10-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of sars-cov-2 infection |
WO2022008597A1 (en) | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
CA3198468A1 (en) * | 2020-10-30 | 2022-05-05 | Daiichi Sankyo Company, Limited | Production method for 3-methyl-4-haloindole derivatives |
WO2023164612A1 (en) * | 2022-02-25 | 2023-08-31 | Nalo Therapeutics | Modulators of myc family proto-oncogene protein |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE294797T1 (de) | 2000-09-15 | 2005-05-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
PL210066B1 (pl) * | 2000-12-21 | 2011-11-30 | Vertex Pharma | Związek pirazolowy, kompozycja zawierająca ten związek i jego zastosowania |
GB0128134D0 (en) | 2001-11-23 | 2002-01-16 | Syngenta Participations Ag | A product for use in agriculture or horticulture |
EP1663242B1 (en) | 2003-08-07 | 2011-04-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
EP1877057A1 (en) | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
JP2008540622A (ja) * | 2005-05-16 | 2008-11-20 | アストラゼネカ アクチボラグ | 化合物 |
DK1945631T3 (da) * | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
KR20080066069A (ko) | 2005-11-03 | 2008-07-15 | 버텍스 파마슈티칼스 인코포레이티드 | 키나제 억제제로서 유용한 아미노피리미딘 |
EP1951716B1 (en) | 2005-11-16 | 2011-05-04 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as kinase inhibitors |
AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
MX2009011810A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Tiazoles y pirazoles utiles como inhibidores de cinasa. |
JP2010528021A (ja) | 2007-05-24 | 2010-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール |
EP2265270A1 (en) * | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
KR101663637B1 (ko) * | 2009-11-13 | 2016-10-07 | 제노스코 | 키나아제 억제제 |
BR112014015549A8 (pt) * | 2011-12-22 | 2017-07-04 | Hoffmann La Roche | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção |
-
2012
- 2012-08-24 CA CA2844729A patent/CA2844729A1/en not_active Abandoned
- 2012-08-24 CN CN201280052602.0A patent/CN104024248A/zh active Pending
- 2012-08-24 MX MX2014002208A patent/MX2014002208A/es unknown
- 2012-08-24 US US13/593,776 patent/US8637537B2/en not_active Expired - Fee Related
- 2012-08-24 JP JP2014526505A patent/JP2014524456A/ja active Pending
- 2012-08-24 KR KR1020147007703A patent/KR20140062079A/ko not_active Application Discontinuation
- 2012-08-24 EP EP12755816.1A patent/EP2748159A1/en not_active Withdrawn
- 2012-08-24 WO PCT/EP2012/066468 patent/WO2013026914A1/en active Application Filing
- 2012-08-24 BR BR112014003997A patent/BR112014003997A2/pt not_active IP Right Cessation
- 2012-08-24 RU RU2014109897/04A patent/RU2014109897A/ru not_active Application Discontinuation
-
2014
- 2014-10-22 HK HK14110532A patent/HK1197232A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2844729A1 (en) | 2013-02-28 |
CN104024248A (zh) | 2014-09-03 |
MX2014002208A (es) | 2014-05-28 |
WO2013026914A1 (en) | 2013-02-28 |
RU2014109897A (ru) | 2015-09-27 |
HK1197232A1 (en) | 2015-01-09 |
US8637537B2 (en) | 2014-01-28 |
JP2014524456A (ja) | 2014-09-22 |
KR20140062079A (ko) | 2014-05-22 |
EP2748159A1 (en) | 2014-07-02 |
US20130225620A1 (en) | 2013-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014003997A2 (pt) | composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição | |
BR112015007061A2 (pt) | composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente | |
BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
IL228209B (en) | A composition comprising a chromium-insulin complex and uses therefor for treating a glucose metabolism-related disease or disorder | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
BR112014009528A2 (pt) | métodos e composições para tratar eritropoiese ineficaz | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
BR112015010501A2 (pt) | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada | |
BR112014004182A2 (pt) | métodos para tratar a hepatite c, para tratamento contra o vírus da hepatite c, e para prevenir ou tratar a hepatite c, e, composição | |
LT2729151T (lt) | Farmacinė kompozicija, gydymo būdai ir jų panaudojimas | |
BR112013018679A2 (pt) | agente para o tratamento da alopecia | |
BR112014005235A2 (pt) | composto heterocíclico, composição farmacêutica, agente profilático e/ou terapêutico, e, método para prevenir e/ou tratar uma doença neurológica central | |
BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
EP2903616B8 (en) | Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer | |
BR112015002739A2 (pt) | métodos para intensificar, melhorar ou sustentar saúde e/ou função cognitiva em mamíferos, e para tratar ou prevenir um declínio em saúde e/ou função cognitiva em mamíferos | |
BR112013033078A2 (pt) | partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente | |
EP2729156A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF FAT PATRICK SKIN TYPES IV, V AND VI | |
EP2842568A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF TYPE I DIABETES AND THE USE THEREOF | |
BR112014031899A8 (pt) | composto, composição farmacêutica, e, método para tratamento de um distúrbio | |
BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
BR112014015549A8 (pt) | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção | |
FI20115078A0 (fi) | Maanpeitekate, katteen käsittelyaine ja menetelmä maanpeitekatteen valmistamiseksi ja katteen ja käsittelyaineen käyttö |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |